Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial

• Egile Nagusiak: Sadahiro Naka (Egilea), Kazuhiro Ooe (Egilea), Yoshifumi Shirakami (Egilea), Kenta Kurimoto (Egilea), Toshihiro Sakai (Egilea), Kazuhiro Takahashi (Egilea), Atsushi Toyoshima (Egilea), Yang Wang (Egilea), Hiromitsu Haba (Egilea), Hiroki Kato (Egilea), Noriyuki Tomiyama (Egilea), Tadashi Watabe (Egilea)
• Formatua: Liburua
• Argitaratua: SpringerOpen, 2024-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background The alpha emitter astatine-211 (211At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid cancer resistant to conventional therapy using beta emitter radioiodine (131I). Herein, we aimed to establish a robust method for the manufacturing...